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Abstract
A family is reported in which three male siblings of Asian descent developed non-Hodgkin’s lymphoma (NHL).
Case 1 was diagnosed with indolent follicular lymphoma stage IIIA at age 45. Case 2 presented with large B-cell
lymphoma stage IIB at age 56. Chromosomal investigation of the peripheral blood did not show abnormalities.
Chemotherapy induced a complete remission. However, after a period of nearly ten years he developed acute
myeloid leukaemia. Case 3 developed large B-cell lymphoma stage IVA at age 52. Cytogenetic analysis in peripheral
blood was normal. Shared genetic and environmental risk factors remain to be identified in this family. Familial
aggregation of NHL is uncommon. In some families, various forms of immunodeficiency have been found. In
addition to coincidental clustering of cases, and rare cases explained by known tumour syndromes such as 
Li-Fraumeni (like) syndrome, other familial cases may share as yet unknown genetic and/or environmental risk factors.
Introduction
In Western countries there has been a large and
mainly unexplained rise in incidence of non- Hodgkin’s
lymphoma (NHL) in recent years [1]. Several aetiological
factors for NHL are known, including genetic and
environmental or occupational factors. Familial
aggregation of lymphoproliferative malignancies
(malignant lymphoma and lymphatic leukaemia) has
been reported repeatedly but accounts for only a small
proportion of lymphoma cases. Most of the familial
cases are sibling pairs either alone or in combination
with other affected relatives. A population-based study
in Israel among first-degree relatives of patients with
lymphomas showed that only 0.7% of the lymphoma
patients had a history of lymphoma in one or more
relatives [2]. In some families, a pre-existing immune
deficiency has been described [3-5]. No histological
subtype appears to predominate in familial cases.
Here, a family in which all three living male siblings
of Asian descent developed NHL is presented. 
Case reports
Case 1
This patient was born in 1936 in East Java
(Indonesia), as were his three younger brothers. His
father worked as a tea planter and died in 1944 at age
38 in a prisoner-of-war camp. A younger brother also
died in a prisoner-of-war camp at age 6. In East Java
there was no overt pollution. In 1957 the remaining
three brothers and their healthy mother emigrated to
the Netherlands. The patient worked as a technical
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chemist. He smoked forty pack years and had always
been healthy until 1981 when follicular lymphoma
stage IIIA was diagnosed at age 45. He was treated
with twelve cycles of COP (cyclophosphamide, oncovin
and prednisone). In 1994 he developed a relapse of
his indolent lymphoma with mediastinal and abdominal
localization for which again COP chemotherapy was
given. In 1997 a second relapse of his lymphoma with
mediastinal localization was noted. Once more the
COP regimen was started which induced a complete
remission. At present he is well without evidence of
recurrent lymphoma.
Case 2
The second living brother was born in 1937. In the
Netherlands he worked as a construction fitter visiting
several factories. He also smoked (approximately twelve
pack years) and had always been healthy until
December 1993 when at age 56 diffuse large B-cell
lymphoma (DLBCL) was diagnosed, stage II A with
localizations in the axilla, cervical region and
nasopharynx. Primary treatment consisted of six cycles
of CHOP (cyclophosphamide, oncovin, adriamycine
and prednisone), which resulted in a complete
remission. No additional therapy was given. In July
2003 he presented with weight loss, fever and enlarged
cervical glands. Acute myeloid leukaemia was
diagnosed. The leukaemia was treated with
daunorubicine and cytarabine followed by a course of
high-dose cytarabine. After an initial response a relapse
of his leukaemia occurred in July 2004. At the moment
he is being treated on an experimental basis.
Chromosomal investigation in peripheral blood has
been performed without finding any abnormalities.
Case 3
The third living brother was born in 1942. As a
technician he worked with acids, alkalis, cyanide and
metals. He smoked eight pack years and was well until
March 2004 when DLBCL stage IVA was diagnosed
with paravertebral localization and myelum
compression causing neurological symptoms. There
was also bone marrow involvement. He was treated
initially with CHOP chemotherapy, in total eight cycles,
followed by rituximab infusions, four cycles. He
responded very well. CT-scan showed a complete
regression of the paravertebral mass. Bone marrow
biopsy, however, revealed a sporadic focus of
lymphoma. Chromosomal investigation of the
peripheral blood did not show abnormalities. 
Unfortunately, three months after completion of the
therapy he developed a relapse with cervical and
retroperitoneal localizations. Simultaneously he was
diagnosed with right-sided oculomotor nerve palsy.
Neurological examination, including CT and MRI of
the brain, did not reveal meningeal involvement but
the cerebrospinal fluid was positive for lymphoma cells.
He was referred for further second-line chemotherapy.
The family history was unremarkable for other types
of cancer and did not meet clinical criteria for Li-
Fraumeni syndrome or any of the other known human
tumour syndromes. There were no symptoms to suggest
immunodeficiency in this family. 
Discussion
Risk of NHL has been found significantly increased in
relatives of people with haematological malignancies,
especially among siblings, although the absolute risk is
small [2, 6, 7]. It has been estimated that the absolute
lifetime risk for a first-degree relative of an NHL case of
developing NHL is 3.6% (compared with a population
risk of 2.1%) and higher if the index case had an
aggressive subtype of NHL [8]. Aggregation of NHL
seems to be stronger for siblings and for male relatives
and among relatives of early-onset (<50 years) NHL
cases [9]. With the exception of chronic lymphocytic
leukaemia and indolent lymphoma, most affected families
present with diverse lymphoproliferative and other
haematological malignancies [10]. This diversity is not
completely unexpected as lymphoma and leukaemia
have common cellular origins, and some types have
common genetic somatic changes or share common
aetiological factors. Histological subtypes do appear to
have an effect on familial risk. A recent study using the
Swedish Family-Cancer Database calculated standardized
incidence ratios (SIRs) for histopathology-specific subtypes
of NHL in offspring with NHL whose parents or siblings
were affected with different types of lymphoproliferative
malignancies. A family history of NHL significantly
increased the risk for NHL (SIRparent=1.8;
SIRsibling=1.9) and for diffuse large B-cell lymphoma
(SIRparent=2.3), follicular lymphoma (SIRsibling=2.3),
and B-cell lymphoma not otherwise specified (NOS)
(SIRsibling=3.4). For a parental history of histopathology-
specific concordant cancer, the risks were significantly
increased for diffuse large B-cell lymphoma (SIR=11.8),
follicular NHL (SIR=6.1), plasma cell myeloma (SIR=2.5),
and chronic lymphocytic leukaemia (SIR=5.9) [11]. 
In general, familial aggregation of lymphoproliferative
malignancies may be coincidental or may be caused by
(combinations of) shared genetic and environmental risk
factors. In rare cases, familial aggregation is associated
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with rare hereditary tumour syndromes such as 
Li-Fraumeni syndrome or hereditary immunodeficiency
syndromes. Apart from those cases occurring in families
meeting the criteria of Li-Fraumeni (like) syndrome,
constitutional p53 mutations are rare in cases of familial
aggregation of lymphoma [12]. Some multiple-case
families have been found to have various types of immune
deficiency disorders [3, 4]. The immunological disorders
range from X-linked lymphoproliferative syndrome and
ataxia telangiectasia to subtle laboratory findings like
a disturbance in T cell function, decreased T cell
number, or increased immunoglobulins. In other
families risk factors are unclear. An argument in favour
of genetic predisposition playing a role is the fact that
various investigators have demonstrated that
anticipation is present in familial NHL [13, 14].
Anticipation is a phenomenon characterised by an
increase in severity of clinical symptoms or a decrease
in the age of onset in successive generations. A possible
non-genetic explanation is that the parents and children
have been simultaneously exposed to a causative
environmental agent, the difference in age of onset
reflecting the generational difference. However, this
does not explain cases in families who did not live
together and cases where parents were diagnosed with
NHL many years after their children were. 
A population-based case-control study in the United
States showed that certain non-genetic risk factors,
including exposure to a chlorinated hydrocarbon
pesticide, plywood, fibreboard or particleboard and
history of liver diseases (other than hepatitis or cirrhosis)
(OR=6.5, 95% CI: 1.2–36.2), increased the risk of NHL
in patients with a family history of haematological
malignancies compared to patients without such family
history [15]. Another study could not confirm that a family
history of cancer modifies the association of agricultural
exposures with NHL [16] and a more recent study showed
no evidence that aetiological associations varied between
familial NHL and nonfamilial NHL cases [7]. In general,
it is therefore still difficult to pinpoint interactions between
shared inherited and environmental risk factors with
respect to NHL development. 
In the present family, no signs of impaired immunity
were present; however, neither cancer predisposing
germline gene mutations nor exposure to viruses or
environmental carcinogens can be excluded. All three
affected brothers may have been exposed to possible
carcinogenic materials during work, and all three were
smokers. Tobacco use has been suggested to increase
the risk of NHL, but the results of epidemiological
studies have been inconsistent [17]. The combined
effects of genetic susceptibility and tobacco use could
possibly lead to NHL. At diagnosis, one brother had
indolent lymphoma and two had aggressive lymphoma
of follicle centre cell origin. It is possible that this was
a transformed lymphoma, which originated also from
an indolent lymphoma, but this could not be
substantiated by available clinical and morphological
data. The leukaemia of case 2 could have been
secondary to chemotherapy or could have been a
second primary haematological malignancy, which
would then again suggest possible predisposition. 
In conclusion: in this case report we have presented
a quite remarkable clinical finding in three male siblings
who developed malignant lymphoma. All of them are still
alive. Shared genetic or environmental risk factors, or
combinations of these, remain to be identified in this family. 
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